Positive preliminary data from InSight extension study of sepofarsen for LCA10 reported – consistent with benefit seen in Phase 1/2 and building confidence in Phase 2/3 Illuminate trial;
Strategic convertible debt financing extends runway into 2023 if fully draw
… ProQR Announces FinancialResults for the Third Quarter of 2018 LEIDEN, … of sterilization on oligonucleotide based drug products Financial Highlights At September 30, 2018, ProQR held cash …
… ProQR Announces FinancialResults for the Second Quarter of 2018 LEIDEN, The … modulation to treat USH2A-associated retinal degeneration Financial Highlights At June 30, 2018, ProQR held cash and …
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020
QR-1123 Investigational New Drug application active for autosomal dominant re
… ProQR Announces Fourth Quarter and Full Year 2019 Results and Provides Business Update Substantial progress in … for severe genetic rare diseases, today reported its financialresults for the fourth quarter and full year ended …